Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jul-Aug;8(4):226-36.
doi: 10.1007/s11307-006-0041-8.

Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers

Yun Wu  1 , Weibo Cai, Xiaoyuan Chen
Affiliations

Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers

Yun Wu et al. Mol Imaging Biol. 2006 Jul-Aug.

Abstract

Purpose: Cell adhesion molecule integrin alpha v beta 3 is an excellent target for tumor interventions because of its unique expression on the surface of several types of solid tumor cells and on almost all sprouting tumor vasculatures. Here, we describe the development of near-infrared (NIR) fluorochrome Cy7-labeled RGD peptides for tumor integrin targeting.

Procedures: Mono-, di-, and tetrameric RGD peptides were synthesized and conjugated with Cy7. The integrin specificity of these fluorescent probes was tested in vitro for receptor binding assay and fluorescence microscopy and in vivo for subcutaneous U87MG tumor targeting.

Results: The tetrameric RGD peptide probe with the highest integrin affinity showed the highest tumor activity accumulation and strongest tumor-to-normal tissue contrast. This uptake is integrin-specific as the signal accumulated in the tumor can be effectively blocked by unconjugated RGD peptide antagonist of integrin alpha v beta 3.

Conclusions: Noninvasive NIR fluorescence imaging is able to detect and semiquantify tumor integrin expression based upon the highly potent tetrameric RGD peptide probe.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chemical structures of Cy7-c(RGDyK), Cy7-E[c(RGDyK)]2, and Cy7-E{E[c(RGDyK)]2}2.
Fig. 2
Fig. 2
(A) In vitro inhibition of 125I-echistatin binding to integrin αvβ3 expressed on U87MG cells by c(RGDyK) (▪), E[c(EGDyK)]2 (▴), and E{E[c(EGDyK)]2}2 (▾). (B) In vitro inhibition of 125I-echistatin binding to integrin αvβ3 expressed on U87MG cells by Cy7-c(RGDyK) (□), Cy7-E[c(RGDyK)]2 (▵), and Cy7-E{E[c(RGDyK)]2}2 (▽). All data points were acquired from triplicates.
Fig. 3
Fig. 3
Fluorescence microscopy images of U87MG cells stained with 1 μM of Cy7, Cy7-c(RGDyK), Cy7-E[c(RGDyK)]2, and Cy7-E{E[c(RGDyK)]2}2 without (Experiment A–D: brightfield images; Experiment E–H: fluorescence images) and with (Block I–L: brightfield images; Block M–P: fluorescence images) 20 μM c(RGDyK).
Fig. 4
Fig. 4
Direct comparison of whole-body NIR fluorescence imaging of subcutaneous U87MG tumor-bearing mice injected with 500 pmol Cy7, Cy7-c(RGDyK), Cy7-E[c(RGDyK)]2, or Cy7-E{E[c(RGDyK)]2}2 at 30 minutes, 1 hour, 2 hours, 4 hours, and 24 hours, p.i. Tumors are indicated by arrows and all images are normalized to the same scale.
Fig. 5
Fig. 5
(A) Fluorescence intensity (p/s/cm2/sr) of the tumor as a function of time after injection of Cy7 (○), Cy7-c(RGDyK) (▴), Cy7-E[c(RGDyK)]2 (▾), or Cy7-E{E[c(RGDyK)]2}2 (•). (B) Tumor contrast (tumor/normal tissue ratio) as a function of time postadministration of the Cy7-RGD conjugates.
Fig. 6
Fig. 6
(A) Representative in vivo NIR fluorescence imaging (90° mounting angle) of U87MG tumor-bearing mice injected with Cy7-RGD conjugates (500 pmol) with (Block) and without (Control) coinjection of 200 μg/mouse of c(RGDyK) at 2 hours, p.i. Tumors are indicated by arrows. (B) Representative fluorescence images of dissected U87MG tumor and major organs and tissues after noninvasive imaging at 2 hours p.i.. From left to right: U87MG tumor, muscle, liver, kidney, and intestine.
Fig. 7
Fig. 7
(A) ROI analysis of fluorescence intensity in vivo of U87MG tumor with (Block) and without (Experiment) coinjection of blocking dose of c(RGDyK) at 2 hours, p.i. (B) ROI analysis of dissected tumors of the same mice described in A. (C) Serum stability of Cy7-c(RGDyK). Fluorescence intensity at 775 nm over time was plotted (excitation: 720 nm).
See this image and copyright information in PMC

References

    1. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697–715. - PubMed
    1. Xiong JP, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg–Gly–Asp ligand. Science. 2002;296:151–155. - PubMed
    1. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 1994;264:569–571. - PubMed
    1. Kumar CC. Integrin αvβ3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003;4:123–131. - PubMed
    1. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100. - PubMed

Publication types

MeSH terms

LinkOut - more resources